Abstract
Precision medicine offers remarkable potential for the treatment of cancer, but is largely focused on tumors that harbor actionable mutations. Gene expression signatures can expand the scope of precision medicine by predicting response to traditional (cytotoxic) chemotherapy agents without relying on changes in mutational status. We present a novel signature extraction method, inspired by the principle of convergent evolution, which states that tumors with disparate genetic backgrounds may evolve similar phenotypes independently. This evolutionary-informed method can be utilized to produce signatures predictive of response to over 200 chemotherapeutic drugs found in the Genomics of Drug Sensitivity in Cancer Database. Here, we demonstrate its use by extracting the Cisplatin Response Signature, CisSig, for use in predicting a common trait (sensitivity to cisplatin) across disparate tumor subtypes (epithelial-origin tumors). CisSig is predictive of cisplatin response within the cell lines and clinical trends in independent datasets of tumor samples. Finally, we demonstrate preliminary validation of CisSig for use in muscle-invasive cancer, predicting overall survival in patients who undergo cisplatin-containing chemotherapy. This novel methodology can be used to produce robust signatures for the prediction of traditional chemotherapeutic response, dramatically increasing the reach of personalized medicine in cancer.
Translational Relevance Most precision medicine research focuses on using targeted drugs on patients with known driver mutations, yet the majority of patients don’t have actionable mutations. Using a novel signature extraction method, we produce the Cisplatin Response Signature (CisSig) to predict how well patients with epithelial-origin tumors will respond to cisplatin, a common cytotoxic chemotherapy. We show that expression of CisSig is correlated to clinical trends of cisplatin use in treatment guidelines using independent tumor databases. Then, we look at preliminary validation of CisSig for use in patients with muscle-invasive bladder cancer. Using two independent cohorts of pre-treatment tumor samples, we show that a CisSig-trained model is predictive of overall survival in patients who did receive cisplatin, but this signal is lost in patients who did not receive cisplatin–indicating that the model is predictive of therapeutic response, not simply prognosis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the following NIH grants: 5R37CA244613-02, T32GM007250, and 1F30CA257076-01. Additionally, it was funded by the American Cancer Society (RSG-20-096-01).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Genomics of Drug Sensitivity in Cancer (GDSC) dataset was accessed using R (code in the cited GitHub repository) to directly download files from the following links, which do not require registration: https://www.cancerrxgene.org/gdsc1000/GDSC1000_WebResources//Data/preprocessed/Cell_line_RMA_proc_basalExp.txt.zip, ftp://ftp.sanger.ac.uk/pub/project/cancerrxgene/releases/current_release/GDSC2_fitted_dose_response_25Feb20.xlsx, ftp://ftp.sanger.ac.uk/pub/project/cancerrxgene/releases/current_release/Cell_Lines_Details.xlsx. The Cancer Genome Atlas (TCGA) dataset was accessed using the `RTCGAToolbox` R package (code in the cided GitHub repository) to download each disease site's RSEM normalized RNASeq V2 (labeled `RNASeq2GeneNorm`). The data can be accessed, without registration here: https://gdac.broadinstitute.org/. The Total Cancer Care (TCC) dataset requires application for access, and can be found here: https://moffitt.org/research-science/total-cancer-care/. Approval was received to use the anonymized data in this manuscript after registration, and the IRB of Moffitt Cancer Center gave ethical approval for the collection of the original data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The authors declare no potential conflicts of interest.
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
1
Blogs/Media
Author Videos